HGG-01. ENTRECTINIB IN RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS: UPDATED DATA IN CHILDREN AND ADOLESCENTS

STARTRK-NG (phase 1/2) is evaluating entrectinib, a CNS-penetrant oral, TRK/ROS1/ALK tyrosine kinase inhibitor, in patients <21 years with recurrent/refractory solid tumors, including primary CNS tumors. After determining the recommended dose, 550mg/m(2)/day, in all-comers, expansion cohorts with...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Robinson, Giles, Desai, Ami, Basu, Ellen, Foster, Jennifer, Gauvain, Karen, Sabnis, Amit, Shusterman, Suzanne, Macy, Margaret, Mease, Luke, Yoon, Janet, Cash, Thomas, Abdelbaki, Mohamed, Nazemi, Kellie, Pratilas, Christine, Weiss, Brian, Chohan, Saibah, Cardenas, Alison, Hutchinson, Katherine, Bergthold, Guillaume, Gajjar, Amar
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
High Grade Glioma
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715329/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.293
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars